up 16c, page-44

Auto, I'll take you up on that offer. Many of these will probably be asked by others but here goes:

1. Vapendavir.

(a) what is the thinking behind expanding the indication (is this being driven internally or by outside parties?)
(b) what happened to the interest in the original indication by outside parties (i.e. the ones that helped us structure the Phase 2b trial)?
(c) Give us a firmer timeline for review completion (they said "few quarters" back in April).

2. RSV

(a) we've had 2 failures in this program. why continue this program?
(b) give timelines on when this might get into the clinic

3. Gram Negative

(a) does this program have any potential for dual use purposes (i.e. biodefense)
(b) what are the chances of attracting BARDA type funding?

4. LANI

(a) what is the potential competitive threat posed by Favipiravir and Fludase? Should we be concerned?

5. Other

(a) Have we had any interest in any of our non-core programs being out-licensed? How does he rate our chances out-licensing these?